Revolution Medicines, Inc.
RVMD
$203.71
$1.710.85%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 1.30B | 1.13B | 987.33M | 880.49M | 769.73M |
| Gross Profit | -1.30B | -1.13B | -987.33M | -880.49M | -769.73M |
| SG&A Expenses | 330.91M | 261.28M | 195.04M | 156.57M | 127.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.63B | 1.39B | 1.18B | 1.04B | 897.50M |
| Operating Income | -1.63B | -1.39B | -1.18B | -1.04B | -897.50M |
| Income Before Tax | -1.77B | -1.37B | -1.13B | -961.73M | -812.81M |
| Income Tax Expenses | -- | -- | -- | -753.00K | -753.00K |
| Earnings from Continuing Operations | -1.77K | -1.37K | -1.13K | -960.98 | -812.06 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.77B | -1.37B | -1.13B | -960.98M | -812.06M |
| EBIT | -1.63B | -1.39B | -1.18B | -1.04B | -897.50M |
| EBITDA | -1.62B | -1.38B | -1.17B | -1.03B | -890.70M |
| EPS Basic | -8.81 | -7.07 | -5.92 | -5.18 | -4.50 |
| Normalized Basic EPS | -5.51 | -4.42 | -3.70 | -3.24 | -2.82 |
| EPS Diluted | -8.81 | -7.07 | -5.92 | -5.18 | -4.50 |
| Normalized Diluted EPS | -5.51 | -4.42 | -3.70 | -3.24 | -2.82 |
| Average Basic Shares Outstanding | 794.89M | 772.58M | 762.63M | 739.72M | 717.33M |
| Average Diluted Shares Outstanding | 794.89M | 772.58M | 762.63M | 739.72M | 717.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |